How does gbs occur

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Guillain-Barré syndrome (GBS) occurs when the body's immune system mistakenly attacks the peripheral nerves, often triggered by an infection. About two-thirds of cases follow respiratory or gastrointestinal infections, with Campylobacter jejuni being the most common bacterial trigger. GBS affects approximately 1-2 people per 100,000 annually worldwide, with peak incidence in adults aged 50-70. The condition typically begins with weakness and tingling in the legs that spreads upward, potentially leading to paralysis within days to weeks.

Key Facts

GBS affects 1-2 people per 100,000 annually worldwide
Approximately 60-70% of cases follow respiratory or gastrointestinal infections
Campylobacter jejuni infection is the most common bacterial trigger (30% of cases)
Peak incidence occurs in adults aged 50-70 years
About 15-20% of patients experience severe disability despite treatment

Overview

Guillain-Barré syndrome (GBS) is a rare autoimmune disorder where the body's immune system attacks the peripheral nervous system, leading to rapid-onset muscle weakness and sometimes paralysis. First described by French neurologists Georges Guillain and Jean Alexandre Barré in 1916, GBS gained significant attention during the 1976 U.S. swine flu vaccination campaign when an increased incidence was observed. The condition affects approximately 1-2 people per 100,000 annually worldwide, with no gender predilection. While it can occur at any age, incidence increases with age, peaking in adults 50-70 years old. GBS represents the most common cause of acute flaccid paralysis worldwide since the near-eradication of polio. The economic burden is substantial, with hospitalizations costing an average of $318,966 per patient in the U.S. according to 2016 data.

How It Works

GBS occurs through an autoimmune mechanism where antibodies mistakenly target peripheral nerve components, particularly the myelin sheath (in the demyelinating form) or the axon itself (in axonal forms). This immune response is typically triggered by molecular mimicry, where antigens from preceding infections resemble nerve tissue proteins. The most common trigger is Campylobacter jejuni gastroenteritis, accounting for about 30% of cases. Other triggers include cytomegalovirus (15% of cases), Epstein-Barr virus, Zika virus, and Mycoplasma pneumoniae. Following infection, activated T-cells and antibodies cross-react with gangliosides (GM1, GD1a) on nerve surfaces. This triggers complement activation, inflammation, and damage to the myelin sheath or axon, disrupting nerve signal transmission. The damage typically begins in the nerve roots near the spinal cord and progresses distally, explaining why symptoms often start in the legs and ascend.

Why It Matters

GBS matters because it represents a medical emergency requiring prompt recognition and treatment to prevent severe disability or death. Approximately 15-20% of patients experience significant long-term disability despite treatment, with 3-5% mortality rate even in modern healthcare settings. The condition has significant public health implications, as evidenced by associations with vaccination campaigns (1976 swine flu, 2009 H1N1) and outbreaks (2015-2016 Zika virus epidemic in Latin America). Early treatment with intravenous immunoglobulin or plasma exchange can reduce recovery time from months to weeks. GBS research has advanced understanding of autoimmune neurology and informed development of treatments for other autoimmune conditions. The economic impact is substantial, with average hospital stays of 19 days and significant rehabilitation costs.